{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:49Z","timestamp":1792783549330,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Abbott India Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s43032-023-01302-z","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:01:57Z","timestamp":1690203717000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Role of Dydrogesterone for Luteal Phase Support in Assisted Reproduction"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-4991","authenticated-orcid":false,"given":"Ameet","family":"Patki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"issue":"Suppl 161","key":"1302_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/aogs.12771","volume":"94","author":"S Taraborrelli","year":"2015","unstructured":"Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94(Suppl 161):8\u201316. https:\/\/doi.org\/10.1111\/aogs.12771.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"1302_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.rbmo.2018.11.017","volume":"38","author":"G Griesinger","year":"2019","unstructured":"Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249\u201359. https:\/\/doi.org\/10.1016\/j.rbmo.2018.11.017.","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"1302_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/13697137.2018.1436166","volume":"21","author":"HJA Carp","year":"2018","unstructured":"Carp HJA. Progestogens and pregnancy loss. Climacteric. 2018;21(4):380\u20134. https:\/\/doi.org\/10.1080\/13697137.2018.1436166.","journal-title":"Climacteric"},{"issue":"2","key":"1302_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00006254-197802000-00001","volume":"33","author":"AI Csapo","year":"1978","unstructured":"Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence Obstet Gynecol Surv. 1978;33(2):69\u201381. https:\/\/doi.org\/10.1097\/00006254-197802000-00001.","journal-title":"Luteectomy evidence Obstet Gynecol Surv"},{"issue":"2","key":"1302_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s0015-0282(03)00663-0","volume":"80","author":"EM Kolibianakis","year":"2003","unstructured":"Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC, Devroey P. Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril. 2003;80(2):464\u20136. https:\/\/doi.org\/10.1016\/s0015-0282(03)00663-0.","journal-title":"Fertil Steril"},{"key":"1302_CR6","doi-asserted-by":"publisher","unstructured":"The Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2012;98(5):1112\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.06.050.","DOI":"10.1016\/j.fertnstert.2012.06.050"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"CD009154","DOI":"10.1002\/14651858.CD009154.pub3","volume":"7","author":"M van der Linden","year":"2015","unstructured":"van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. 2015 Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154. https:\/\/doi.org\/10.1002\/14651858.CD009154.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1302_CR8","doi-asserted-by":"publisher","unstructured":"The Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789\u201392. https:\/\/doi.org\/10.1016\/j.fertnstert.2008.02.012","DOI":"10.1016\/j.fertnstert.2008.02.012"},{"issue":"5","key":"1302_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.fertnstert.2018.03.034","volume":"109","author":"G Griesinger","year":"2018","unstructured":"Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018;109(5):756\u201362. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.03.034.","journal-title":"Fertil Steril"},{"issue":"10","key":"1302_CR10","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/humrep\/dex266","volume":"32","author":"H Tournaye","year":"2017","unstructured":"Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(10):2152. https:\/\/doi.org\/10.1093\/humrep\/dex266.","journal-title":"Hum Reprod"},{"issue":"12","key":"1302_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/humrep\/dey306","volume":"33","author":"G Griesinger","year":"2018","unstructured":"Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;33(12):2212\u201321. https:\/\/doi.org\/10.1093\/humrep\/dey306.","journal-title":"Hum Reprod"},{"issue":"5","key":"1302_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jsbmb.2005.08.012","volume":"97","author":"BN Chakravarty","year":"2005","unstructured":"Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005;97(5):416\u201320. https:\/\/doi.org\/10.1016\/j.jsbmb.2005.08.012.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"1302_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/humupd\/dmt030","volume":"19","author":"ER Groenewoud","year":"2013","unstructured":"Groenewoud ER, Cantineau AE, Kollen BJ, Macklon NS, Cohlen BJ. What is the optimal means of preparing the endometrium in frozen-thawed embryo transfer cycles? A systematic review and meta-analysis. Hum Reprod Update. 2013;19(5):458\u201370. https:\/\/doi.org\/10.1093\/humupd\/dmt030.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"1302_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10815-009-9318-6","volume":"26","author":"M RezazadehValojerdi","year":"2009","unstructured":"RezazadehValojerdi M, Eftekhari-Yazdi P, Karimian L, Hassani F, Movaghar B. Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. J Assist Reprod Genet. 2009;26(6):347\u201354. https:\/\/doi.org\/10.1007\/s10815-009-9318-6.","journal-title":"J Assist Reprod Genet"},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/tog.12630","volume":"22","author":"M Noble","year":"2020","unstructured":"Noble M, Child T. The role of frozen\u2013thawed embryo replacement cyclesin assisted conception. Obstet Gynaecol. 2020;22:57\u201368. https:\/\/doi.org\/10.1111\/tog.12630.","journal-title":"Obstet Gynaecol"},{"issue":"5","key":"1302_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/s1043-2760(03)00075-4","volume":"14","author":"BC Fauser","year":"2003","unstructured":"Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14(5):236\u201342. https:\/\/doi.org\/10.1016\/s1043-2760(03)00075-4.","journal-title":"Trends Endocrinol Metab"},{"key":"1302_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13048-015-0205-8","volume":"8","author":"S Palomba","year":"2015","unstructured":"Palomba S, Santagni S, La Sala GB. Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? J Ovarian Res. 2015;8:77. https:\/\/doi.org\/10.1186\/s13048-015-0205-8.","journal-title":"J Ovarian Res"},{"key":"1302_CR18","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.eurox.2019.100046","volume":"3","author":"LTM Chau","year":"2019","unstructured":"Chau LTM, Tu DK, Lehert P, Dung DV, Thanh LQ, Tuan VM. Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100046. https:\/\/doi.org\/10.1016\/j.eurox.2019.100046.","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"1302_CR19","doi-asserted-by":"publisher","first-page":"385049","DOI":"10.1155\/2015\/385049","volume":"2015","author":"M Stimpfel","year":"2015","unstructured":"Stimpfel M, Vrtacnik-Bokal E, Pozlep B, Virant-Klun I. Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients. Int J Endocrinol. 2015;2015:385049. https:\/\/doi.org\/10.1155\/2015\/385049.","journal-title":"Int J Endocrinol."},{"issue":"5","key":"1302_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.rbmo.2014.01.012","volume":"28","author":"C Yding Andersen","year":"2014","unstructured":"Yding Andersen C, Vilbour AK. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online. 2014;28(5):552\u20139. https:\/\/doi.org\/10.1016\/j.rbmo.2014.01.012.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"1302_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0974-1208.153120","volume":"8","author":"M Banker","year":"2015","unstructured":"Banker M, Garcia-Velasco JA. Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. J Hum Reprod Sci. 2015;8(1):13\u20137. https:\/\/doi.org\/10.4103\/0974-1208.153120.","journal-title":"J Hum Reprod Sci"},{"issue":"3","key":"1302_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/s0015-0282(16)54544-0","volume":"56","author":"R Scott","year":"1991","unstructured":"Scott R, Navot D, Liu HC, Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril. 1991;56(3):481\u20134. https:\/\/doi.org\/10.1016\/s0015-0282(16)54544-0.","journal-title":"Fertil Steril"},{"issue":"11","key":"1302_CR23","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1093\/humrep\/dex285","volume":"32","author":"S Mackens","year":"2017","unstructured":"Mackens S, Santos-Ribeiro S, van de Vijver A, Racca A, Van Landuyt L, Tournaye H, et al. Frozen embryo transfer: a review on the optimal endometrial preparation and timing. Hum Reprod. 2017;32(11):2234\u201342. https:\/\/doi.org\/10.1093\/humrep\/dex285.","journal-title":"Hum Reprod"},{"issue":"1","key":"1302_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/rmb2.12254","volume":"18","author":"S Kawachiya","year":"2019","unstructured":"Kawachiya S, Bodri D, Hirosawa T, Yao Serna J, Kuwahara A, Irahara M. Endogenous progesterone levels could predict reproductive outcome in frozen embryo replacement cycles supplemented with synthetic progestogens: A retrospective cohort study. Reprod Med Biol. 2019;18(1):91\u20136. https:\/\/doi.org\/10.1002\/rmb2.12254.","journal-title":"Reprod Med Biol"},{"issue":"41","key":"1302_CR25","first-page":"3256","volume":"94","author":"R Yang","year":"2014","unstructured":"Yang R, Chi H, Chen L, Li R, Liu P, Qiao J. Impact of different luteal support methods on clinical outcomes of frozen-thawed embryo transfer cycles. Zhonghua Yi Xue Za Zhi. 2014;94(41):3256\u20138.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"1302_CR26","first-page":"861","volume":"33","author":"W Guo","year":"2013","unstructured":"Guo W, Chen X, Ye D, He Y, Li P, Niu J, et al. Effects of oral dydrogesterone on clinical outcomes of frozen-thawed embryo transfer cycles. Nan Fang Yi Ke Da Xue Xue Bao. 2013;33(6):861\u20135.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"1","key":"1302_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00404-016-4217-4","volume":"295","author":"A Zarei","year":"2017","unstructured":"Zarei A, Sohail P, Parsanezhad ME, Alborzi S, Samsami A, Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet. 2017;295(1):239\u201346. https:\/\/doi.org\/10.1007\/s00404-016-4217-4.","journal-title":"Arch Gynecol Obstet"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1477-7827-10-107","volume":"10","author":"XR Liu","year":"2012","unstructured":"Liu XR, Mu HQ, Shi Q, Xiao XQ, Qi HB. The optimal duration of progesterone supplementation in pregnant women after IVF\/ICSI: a meta-analysis. Reprod Biol Endocrinol. 2012;10:107. https:\/\/doi.org\/10.1186\/1477-7827-10-107.","journal-title":"Reprod Biol Endocrinol"},{"key":"1302_CR29","doi-asserted-by":"publisher","unstructured":"The Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril. 2008;90(5 Suppl):S163\u20134. https:\/\/doi.org\/10.1016\/j.fertnstert.2008.08.053.","DOI":"10.1016\/j.fertnstert.2008.08.053"},{"key":"1302_CR30","unstructured":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London (UK): RCOG Press. 2004."},{"key":"1302_CR31","doi-asserted-by":"publisher","first-page":"CD009154","DOI":"10.1002\/14651858.CD009154.pub2","volume":"10","author":"M van der Linden","year":"2011","unstructured":"van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;10:CD009154. https:\/\/doi.org\/10.1002\/14651858.CD009154.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1302_CR32","doi-asserted-by":"publisher","first-page":"hoaa067","DOI":"10.1093\/hropen\/hoaa067","volume":"2020","author":"EGGOO Stimulation","year":"2020","unstructured":"Stimulation EGGOO, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. Erratum: ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;2020(4):hoaa067. https:\/\/doi.org\/10.1093\/hropen\/hoaa067.","journal-title":"Hum Reprod Open"},{"issue":"2","key":"1302_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/uog.15814","volume":"48","author":"MW Barbosa","year":"2016","unstructured":"Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016;48(2):161\u201370. https:\/\/doi.org\/10.1002\/uog.15814.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"suppl_1","key":"1302_CR34","doi-asserted-by":"crossref","first-page":"i133","DOI":"10.1093\/oxfordjournals.humrep.a002359","volume":"20","author":"BN Chakravarty","year":"2005","unstructured":"Chakravarty BN, Dam P, Goswami SK, Ghosh S, Chattopadhyay R. Oral dydrogesterone versus vaginal micronised progesterone as luteal phase support in ART cycles\u2013evaluation based on correction of hormone profile and clinical outcome. Human Reprod. 2005;20(suppl_1):i133\u201341.","journal-title":"Human Reprod"},{"issue":"Suppl 1","key":"1302_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/09513590701584857","volume":"23","author":"A Patki","year":"2007","unstructured":"Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007;23(Suppl 1):68\u201372. https:\/\/doi.org\/10.1080\/09513590701584857.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"1302_CR36","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.fertnstert.2011.01.148","volume":"95","author":"A Ganesh","year":"2011","unstructured":"Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95(6):1961\u20135. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.01.148.","journal-title":"Fertil Steril"},{"issue":"3","key":"1302_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/09513590.2015.1110136","volume":"32","author":"N Saharkhiz","year":"2016","unstructured":"Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L, et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol. 2016;32(3):213\u20137. https:\/\/doi.org\/10.3109\/09513590.2015.1110136.","journal-title":"Gynecol Endocrinol"},{"issue":"11","key":"1302_CR38","first-page":"913","volume":"11","author":"S Salehpour","year":"2013","unstructured":"Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial. Iran J Reprod Med. 2013;11(11):913\u20138.","journal-title":"Iran J Reprod Med"},{"key":"1302_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejogrb.2014.11.002","volume":"186","author":"V Tomic","year":"2015","unstructured":"Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;186:49\u201353. https:\/\/doi.org\/10.1016\/j.ejogrb.2014.11.002.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1302_CR40","doi-asserted-by":"publisher","unstructured":"Pabu\u00e7cu E, Pabu\u00e7cu R, G\u00fcrgan T, Tavmergen E. Luteal phase support in fresh and frozen embryo transfer cycles. J Gynecol Obstet Hum Reprod. 2020;49(10):101838. https:\/\/doi.org\/10.1016\/j.jogoh.2020.101838.","DOI":"10.1016\/j.jogoh.2020.101838"},{"issue":"10178","key":"1302_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0140-6736(18)32843-5","volume":"393","author":"D Wei","year":"2019","unstructured":"Wei D, Liu JY, Sun Y, Shi Y, Zhang B, Liu JQ, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. Lancet. 2019;393(10178):1310\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32843-5.","journal-title":"Lancet"},{"issue":"6","key":"1302_CR42","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.rbmo.2022.06.027","volume":"45","author":"E Pabuccu","year":"2022","unstructured":"Pabuccu E, Kovanci E, Israfilova G, Tulek F, Demirel C, Pabuccu R. Oral, vaginal or intramuscular progesterone in programmed frozen embryo transfer cycles: a pilot randomized controlled trial. Reprod Biomed Online. 2022;45(6):1145\u201351. https:\/\/doi.org\/10.1016\/j.rbmo.2022.06.027.","journal-title":"Reprod Biomed Online"},{"key":"1302_CR43","doi-asserted-by":"publisher","unstructured":"Massin N, Pietin-Vialle C, Pasquier M, Heluin G, Haddad B, Bry-Gauillard H. How to implement in real-life settings the results of meta analysis? Example of dydrogesterone as luteal phase support after fresh embryo transfer in IVF procedure. Hum Reprod. 2016;31(suppl_1):i447. https:\/\/doi.org\/10.1093\/humrep\/31.Supplement_1.1.","DOI":"10.1093\/humrep\/31.Supplement_1.1"},{"issue":"5","key":"1302_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1590\/2359-3997000000215","volume":"60","author":"BH Rashidi","year":"2016","unstructured":"Rashidi BH, Gorginzadeh M, Aalipour S, Sills ES. Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center. Arch Endocrinol Metab. 2016;60(5):486\u201391. https:\/\/doi.org\/10.1590\/2359-3997000000215.","journal-title":"Arch Endocrinol Metab."},{"issue":"7","key":"1302_CR45","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1007\/s43032-020-00376-3","volume":"28","author":"Y Atzmon","year":"2021","unstructured":"Atzmon Y, Aslih N, Estrada D, Bilgory A, Ellenbogen A, Shalom-Paz E. Comparable Outcomes Using Oral Dydrogesterone Vs. Micronized Vaginal Progesterone in Frozen Embryo Transfer: a Retrospective Cohort Study. Reprod Sci. 2021;28(7):1874\u201381. https:\/\/doi.org\/10.1007\/s43032-020-00376-3.","journal-title":"Reprod Sci"},{"issue":"5","key":"1302_CR46","doi-asserted-by":"publisher","first-page":"102030","DOI":"10.1016\/j.jogoh.2020.102030","volume":"50","author":"G Ozer","year":"2021","unstructured":"Ozer G, Yuksel B, YucelCicek OS, Kahraman S. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021;50(5):102030. https:\/\/doi.org\/10.1016\/j.jogoh.2020.102030.","journal-title":"J Gynecol Obstet Hum Reprod."},{"key":"1302_CR47","first-page":"295","volume":"11","author":"A Patki","year":"2023","unstructured":"Patki A, Pai H, Shah D, Malik S, Rao K. Evaluating the role of oral dydrogesterone for luteal-phase support in women undergoing frozen embryo transfer: Systematic review with meta-analysis. J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol. 2023;11:295.","journal-title":"J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol"},{"issue":"7","key":"1302_CR48","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/humrep\/deab093","volume":"36","author":"LN Vuong","year":"2021","unstructured":"Vuong LN, Pham TD, Le KTQ, Ly TT, Le HL, Nguyen DTN, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021;36(7):1821\u201331. https:\/\/doi.org\/10.1093\/humrep\/deab093.","journal-title":"Hum Reprod"},{"issue":"7","key":"1302_CR49","doi-asserted-by":"publisher","first-page":"102110","DOI":"10.1016\/j.jogoh.2021.102110","volume":"50","author":"H Xu","year":"2021","unstructured":"Xu H, Zhang XQ, Zhu XL, Weng HN, Xu LQ, Huang L, et al. Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle. J Gynecol Obstet Hum Reprod. 2021;50(7):102110. https:\/\/doi.org\/10.1016\/j.jogoh.2021.102110.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"14","key":"1302_CR50","doi-asserted-by":"publisher","first-page":"1128564","DOI":"10.3389\/fendo.2023.1128564","volume":"13","author":"A Vidal","year":"2023","unstructured":"Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, Schwartz ASK. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone. Front Endocrinol (Lausanne). 2023;13(14):1128564. https:\/\/doi.org\/10.3389\/fendo.2023.1128564.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1302_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/er.2012-1008","volume":"34","author":"FZ Stanczyk","year":"2013","unstructured":"Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171\u2013208. https:\/\/doi.org\/10.1210\/er.2012-1008.","journal-title":"Endocr Rev"},{"issue":"11","key":"1302_CR52","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1210\/jc.2013-3937","volume":"99","author":"RJ Paulson","year":"2014","unstructured":"Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014;99(11):4241\u20139. https:\/\/doi.org\/10.1210\/jc.2013-3937.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"1302_CR53","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","volume":"46","author":"AE Schindler","year":"2003","unstructured":"Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7\u201316. https:\/\/doi.org\/10.1016\/j.maturitas.2003.09.014.","journal-title":"Maturitas"},{"key":"1302_CR54","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.scitotenv.2012.10.092","volume":"443","author":"CG Daughton","year":"2013","unstructured":"Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing \u201cside effects\u201d of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324\u201337. https:\/\/doi.org\/10.1016\/j.scitotenv.2012.10.092.","journal-title":"Sci Total Environ"},{"issue":"3","key":"1302_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MOG.0b013e3283383c7c","volume":"26","author":"M Ghabril","year":"2010","unstructured":"Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010;26(3):222\u20136. https:\/\/doi.org\/10.1097\/MOG.0b013e3283383c7c.","journal-title":"Curr Opin Gastroenterol"},{"issue":"Suppl 1","key":"1302_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13697130500148875","volume":"8","author":"H Kuhl","year":"2005","unstructured":"Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3\u201363. https:\/\/doi.org\/10.1080\/13697130500148875.","journal-title":"Climacteric"},{"issue":"6","key":"1302_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.steroids.2011.02.043","volume":"76","author":"TL Rizner","year":"2011","unstructured":"Rizner TL, Brozic P, Doucette C, Turek-Etienne T, Muller-Vieira U, Sonneveld E, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607\u201315. https:\/\/doi.org\/10.1016\/j.steroids.2011.02.043.","journal-title":"Steroids"},{"key":"1302_CR58","doi-asserted-by":"publisher","unstructured":"Raghupathy R, Szekeres-Bartho J. Progesterone: a unique hormone with immunomodulatory roles in pregnancy. Int J Mol Sci. 2022;23(3):1333. https:\/\/doi.org\/10.3390\/ijms23031333","DOI":"10.3390\/ijms23031333"},{"issue":"7","key":"1302_CR59","doi-asserted-by":"publisher","first-page":"e0220450","DOI":"10.1371\/journal.pone.0220450","volume":"14","author":"A Netter","year":"2019","unstructured":"Netter A, Mancini J, Buffat C, Agostini A, Perrin J, Courbiere B. Do early luteal serum progesterone levels predict the reproductive outcomes in IVF with oral dydrogesterone for luteal phase support? PLoS One. 2019;14(7):e0220450. https:\/\/doi.org\/10.1371\/journal.pone.0220450.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"1302_CR60","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.maturitas.2009.11.013","volume":"65","author":"MY El-Zibdeh","year":"2009","unstructured":"El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65(Suppl 1):S43\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2009.11.013.","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"1302_CR61","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.maturitas.2009.11.016","volume":"65","author":"RU Pandian","year":"2009","unstructured":"Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(Suppl 1):S47-50. https:\/\/doi.org\/10.1016\/j.maturitas.2009.11.016.","journal-title":"Maturitas"},{"issue":"50","key":"1302_CR62","first-page":"1678","volume":"129","author":"ML Ehrenskjold","year":"1967","unstructured":"Ehrenskjold ML, Bondo B, Weile F. Treatment of threatened abortion with dydrogesterone. Ugeskr Laeger. 1967;129(50):1678\u20139.","journal-title":"Ugeskr Laeger"},{"issue":"2","key":"1302_CR63","first-page":"102","volume":"89","author":"A Misto","year":"1967","unstructured":"Misto A. Experiences with 6-dehydro-retroprogesterone int the treatment of placental insufficiency. Ann Ostet Ginecol Med Perinat. 1967;89(2):102\u201312.","journal-title":"Ann Ostet Ginecol Med Perinat"},{"key":"1302_CR64","first-page":"281","volume":"69","author":"E Vincze","year":"2006","unstructured":"Vincze E, Moln\u00e1r B, F\u00f6ldesi I, P\u00e1l A. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. Magyar Noorvosok Lapja. 2006;69:281\u20134.","journal-title":"Magyar Noorvosok Lapja"},{"issue":"5","key":"1302_CR65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jsbmb.2005.08.007","volume":"97","author":"MY El-Zibdeh","year":"2005","unstructured":"El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 2005;97(5):431\u20134. https:\/\/doi.org\/10.1016\/j.jsbmb.2005.08.007.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"1302_CR66","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00246-015-1190-9","volume":"36","author":"M Zaqout","year":"2015","unstructured":"Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy. Pediatr Cardiol. 2015;36(7):1483\u20138. https:\/\/doi.org\/10.1007\/s00246-015-1190-9.","journal-title":"Pediatr Cardiol"},{"issue":"7","key":"1302_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40261-019-00884-4","volume":"40","author":"G Koren","year":"2020","unstructured":"Koren G, Gilboa D, Katz R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig. 2020;40(7):681. https:\/\/doi.org\/10.1007\/s40261-019-00884-4.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1302_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.rbmo.2022.03.032","volume":"45","author":"A Katalinic","year":"2022","unstructured":"Katalinic A, Shulman LP, Strauss JF, Garcia-Velasco JA, van den Anker JN. A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis. Reprod Biomed Online. 2022;45(2):365\u201373. https:\/\/doi.org\/10.1016\/j.rbmo.2022.03.032.","journal-title":"Reprod Biomed Online"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-023-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-023-01302-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-023-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T12:01:57Z","timestamp":1704974517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-023-01302-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s43032-023-01302-z","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this is a review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable as this is a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable as this is a review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The author has received speaker fees and honoraria for educational events from Cipla, Abbott and MSD and travel support for meeting attendance from Abbott.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}